Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
YF
MCID: YLL002
MIFTS: 62

Yellow Fever (YF)

Categories: Infectious diseases, Liver diseases, Muscle diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Yellow Fever

About this section

MalaCards integrated aliases for Yellow Fever:

Name: Yellow Fever 11 19 58 75 53 2 43 14 71 31 33
Urban Yellow Fever 11 71 31
Sylvatic Yellow Fever 11 31
Jungle Yellow Fever 11 71
Yf 19 58
Yellow Fever, Sylvan 11
Yf- [yellow Fever] 33
Febris Flava 33
Bronze John 58
Yellow Jack 58

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Skin diseases Muscle diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare infectious diseases


Sources

Summaries for Yellow Fever

About this section

CDC: 2 The yellow fever virus is found in tropical and subtropical areas of Africa and South America. The virus is spread to people by the bite of an infected mosquito. Yellow fever is a very rare cause of illness in U.S. travelers. Illness ranges from a fever with aches and pains to severe liver disease with bleeding and yellowing skin (jaundice). Yellow fever infection is diagnosed based on laboratory testing, a person's symptoms, and travel history. There is no medicine to treat or cure infection. To prevent getting sick from yellow fever, use insect repellent, wear long-sleeved shirts and long pants, and get vaccinated.

MalaCards based summary: Yellow Fever, also known as urban yellow fever, is related to zika fever and west nile virus. An important gene associated with Yellow Fever is EIF2AK4 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Orange and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and skin, and related phenotypes are fever and increased circulating igm level

Disease Ontology: 11 A viral infectious disease that results in infection, has material basis in Yellow fever virus, which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.

GARD: 19 Yellow fever (YF), caused by YF virus, is a zoonotic disease characterized by fever and constitutional symptoms, with the potential to progress to severe and fatal viral hemorrhagic fever with shock and multi-organ system failure.

Orphanet: 58 Yellow fever (YF), caused by YF virus, is a zoonotic disease characterized by fever and constitutional symptoms, with the potential to progress to severe and fatal viral hemorrhagic fever with shock and multi-organ system failure.

Wikipedia: 75 Yellow fever is a viral disease of typically short duration. In most cases, symptoms include fever,... more...
Sources

Related Diseases for Yellow Fever

About this section

Diseases related to Yellow Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 623)
# Related Disease Score Top Affiliating Genes
1 zika fever 32.3 RIGI IFNB1 IFNAR1
2 west nile virus 32.0 RSAD2 RIGI OAS1 IL17A CCR5
3 dengue disease 32.0 RIGI IL6 IFNB1 IFNAR1 CCL5
4 cholera 31.5 IL6 IL5 IL4 IL1B
5 plague 31.5 RIGI IL6 IL4 IL1B CCR5
6 japanese encephalitis 31.4 RSAD2 RIGI IFNB1 IFNAR1
7 chikungunya 31.3 RSAD2 RIGI IL6 IL1B IL17A CCL5
8 poliomyelitis 31.2 RIGI IL6 IFNB1
9 encephalitis 31.1 RSAD2 RIGI IL6 IL1B IFNB1 CXCL10
10 typhoid fever 31.1 IL6 IL1B IL1A
11 tick-borne encephalitis 31.1 IFNAR1 CXCL10 CCR5
12 meningoencephalitis 31.0 IL6 IL1B CXCL10 CCL5
13 hepatitis a 31.0 IL4 IL1B CXCL10 CCR5
14 ebola hemorrhagic fever 31.0 RIGI IL6 IFNB1 IFNAR1 CXCL10 CCR5
15 dengue hemorrhagic fever 30.9 RIGI IL6 IFNAR1 CXCL10
16 myelitis 30.8 IL6 IL17A IFNB1
17 tetanus 30.8 IL6 IL5 IL4 IL1B IL1A
18 lassa fever 30.8 RIGI IFNB1 IFNAR1
19 vaccinia 30.8 STAT1 IRF7 IL6 IFNB1 CXCL10 CCR5
20 measles 30.7 STAT1 RIGI OAS1 IRF7 IL6 IL1B
21 viral encephalitis 30.7 RIGI IL6 IL1B IFNB1 IFNAR1 CXCL10
22 mumps 30.7 STAT1 IL6 IL1B IFNB1 CXCL10
23 exanthem 30.7 IL6 IL4 IL1B IL17A
24 leptospirosis 30.7 IL6 IL4 IL1B IL1A CCL2
25 dengue shock syndrome 30.7 RIGI IL6 IL1B
26 anterior uveitis 30.6 IL6 IL1B IL17A
27 acute kidney tubular necrosis 30.6 IL6 IL1B CCL2
28 spondyloarthropathy 1 30.5 IL6 IL1B IL17A
29 urticaria 30.5 IL6 IL5 IL4 IL1B IL17A
30 rubella 30.5 RIGI OAS1 IL6 IL5 IL4 IL1B
31 herpes simplex 30.5 STAT1 RSAD2 RIGI OAS1 IFNB1
32 rabies 30.5 STAT1 RIGI IRF7 CXCL10 CCL5
33 hepatitis c 30.4 RIGI IRF7 IFNB1 IFNAR1 CXCL10
34 crimean-congo hemorrhagic fever 30.3 STAT1 IL6 IFNB1 IFNAR1
35 kawasaki disease 30.3 IL1A CCL5 CCL2
36 toxic shock syndrome 30.3 IL6 IL4 IL1B IL1A
37 intermediate uveitis 30.3 IL6 IL17A CCR5
38 respiratory syncytial virus infectious disease 30.3 IL5 IFNB1 CCL5
39 human immunodeficiency virus type 1 30.3 CXCL10 CCR5 CCL5 CCL2
40 diarrhea 30.3 RIGI IL6 IL5 IL1B IFNB1
41 bacterial sepsis 30.3 IL6 IL1B IFNB1 CXCL10 CCL2
42 posterior uveitis 30.3 IL6 IL5 IL17A
43 panuveitis 30.3 IL6 IL1B IL17A
44 viral infectious disease 30.3 STAT1 RIGI OAS1 IRF7 IL6 IL4
45 q fever 30.3 IL6 IL4 IL1B CCL5 CCL2
46 inflammatory bowel disease 1 30.3 IL6 IL1B IL17A
47 severe combined immunodeficiency 30.3 STAT1 IL6 IL5 IL4 IL17A IFNB1
48 human cytomegalovirus infection 30.2 RSAD2 IL6 IL17A IFNB1
49 systemic scleroderma 30.2 IL6 IL4 IL1B IL17A CCL2
50 covid-19 30.2 IL6 IL4 IL1B IFNB1 CXCL10 CCL2

Graphical network of the top 20 diseases related to Yellow Fever:



Diseases related to Yellow Fever
Sources

Symptoms & Phenotypes for Yellow Fever

About this section

Human phenotypes related to Yellow Fever:

58 30 (show top 50) (show all 52)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0001945
2 increased circulating igm level 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0003496
3 viremia 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0020071
4 nausea 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002018
5 elevated circulating alanine aminotransferase concentration 30 Hallmark (90%) HP:0031964
6 vomiting 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002013
7 elevated circulating creatine kinase concentration 58 30 Frequent (33%) Frequent (79-30%)
 HP:0003236
8 abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002027
9 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002829
10 myalgia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0003326
11 hematemesis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002248
12 headache 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002315
13 metabolic acidosis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001942
14 acute kidney injury 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001919
15 bradycardia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001662
16 chills 58 30 Frequent (33%) Frequent (79-30%)
 HP:0025143
17 excessive bleeding after a venipuncture 58 30 Frequent (33%) Frequent (79-30%)
 HP:0030139
18 pancreatic hyperplasia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0006277
19 elevated circulating creatinine concentration 30 Frequent (33%) HP:0003259
20 elevated circulating aspartate aminotransferase concentration 30 Frequent (33%) HP:0031956
21 increased circulating interleukin 6 concentration 30 Frequent (33%) HP:0030783
22 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001873
23 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000952
24 supraventricular arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0005115
25 hyperbilirubinemia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002904
26 prolonged prothrombin time 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0008151
27 coma 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001259
28 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002014
29 leukocytosis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001974
30 neutrophilia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0011897
31 shock 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0031273
32 acute pancreatitis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001735
33 capillary leak 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0030005
34 hypofibrinogenemia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0011900
35 low back pain 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003419
36 reduced coagulation factor v activity 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003225
37 decreased serum bicarbonate concentration 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0032066
38 increased intracranial pressure 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0002516
39 skin rash 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0000988
40 status epilepticus 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0002133
41 anuria 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0100519
42 opportunistic infection 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0031690
43 reduced left ventricular ejection fraction 30 Very rare (1%) HP:0012664
44 seizure 58 Occasional (29-5%)
45 renal insufficiency 58 Frequent (79-30%)
46 internal hemorrhage 58 Very rare (<4-1%)
47 abnormal bleeding 58 Frequent (79-30%)
48 reduced ejection fraction 58 Very rare (<4-1%)
49 elevated serum creatinine 58 Frequent (79-30%)
50 increased serum interleukin-6 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Yellow Fever:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 CCL2 CCR5 CXCL10 EIF2AK4 IFNAR1 IFNB1
2 immune system MP:0005387 10.16 CCL2 CCL5 CCR5 CXCL10 EIF2AK4 IFNAR1
3 liver/biliary system MP:0005370 10.14 CCL2 CCR5 EIF2AK4 IFNAR1 IL17A IL4
4 neoplasm MP:0002006 10.13 CCL2 CCR5 IFNAR1 IFNB1 IL1A IL1B
5 behavior/neurological MP:0005386 10.07 CCL2 CCR5 EIF2AK4 IFNAR1 IL17A IL1A
6 digestive/alimentary MP:0005381 9.97 CCL2 CCR5 IFNAR1 IL17A IL4 IL5
7 hematopoietic system MP:0005397 9.89 CCL2 CCL5 CCR5 CXCL10 EIF2AK4 IFNAR1
8 mortality/aging MP:0010768 9.47 CCL2 CCR5 CXCL10 EIF2AK4 IFNAR1 IL17A
Sources

Drugs & Therapeutics for Yellow Fever

About this section

Drugs for Yellow Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 4
2 Pharmaceutical Solutions Phase 4
3 Immunologic Factors Phase 4
4 Vaccines Phase 4
5
Lactitol Approved, Investigational Phase 3 585-86-4 157355
6
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
7
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
8 Vitamins Phase 3
9 Trace Elements Phase 3
10 Micronutrients Phase 3
11 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
12 Retinol palmitate Phase 3
13
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
14
Tannic acid Approved Phase 1, Phase 2 1401-55-4 16129878 16129778
15
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
16
Altretamine Approved Phase 2 645-05-6 2123
17
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 2 67-97-0, 1406-16-2 5280795 10883523
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
19 Anti-Inflammatory Agents Phase 2
20 Immunoglobulins Phase 1, Phase 2
21 Antibodies Phase 1, Phase 2
22 Immunoglobulin G Phase 1, Phase 2
23 Hormones Phase 2
24 Calciferol Phase 2
25 Calcium, Dietary Phase 2
26 Hypoglycemic Agents Phase 2
27
Calcium Nutraceutical Phase 2 7440-70-2 271
28
Aluminum sulfate Approved Phase 1 10043-01-3
29
Galidesivir Investigational Phase 1 249503-25-1
30 Monatide (IMS 3015) Phase 1
31 Antibodies, Monoclonal Phase 1
32 Immunoglobulins, Intravenous Phase 1
33 gamma-Globulins Phase 1
34 Rho(D) Immune Globulin Phase 1
35 Antiviral Agents Phase 1
36 Anti-Infective Agents Phase 1
37
Methotrexate Approved 1959-05-2, 59-05-2 4112 126941
38
BCG vaccine Approved, Investigational
39 Antibodies, Blocking

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination Unknown status NCT04083430 Phase 4 Yellow Fever Vaccine
2 Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old Unknown status NCT03725618 Phase 4
3 A Randomized, Blinded Non-inferiority Trial on the Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines in Kenya and Uganda Completed NCT02991495 Phase 4
4 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
5 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
6 Human Immune Responses to Yellow Fever Vaccination Recruiting NCT00694655 Phase 4
7 Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine Recruiting NCT04059471 Phase 4
8 Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine Recruiting NCT01290055 Phase 4
9 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
10 Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic Area Active, not recruiting NCT02555072 Phase 4
11 An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine Active, not recruiting NCT05374317 Phase 4
12 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
13 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient Completed NCT01426243 Phase 3
14 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
15 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3 Placebo
16 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine. Completed NCT02699099 Phase 3
17 Yellow Fever Vaccine Booster Trial in Children- a Phase 3 Clinical Trial to Establish Safety and Immunogenicity of Repeated YF Vaccination in Healthy Gambian Children of Different Ages Not yet recruiting NCT05332197 Phase 3
18 A Phase III, Multicenter, Double Blind, Randomized Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL Not yet recruiting NCT05421611 Phase 3
19 A Phase III, Multicenter, Double Blind, Randomized Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants Not yet recruiting NCT05447377 Phase 3
20 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Completed NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
21 An Open-label Phase 2a Clinical Trial to Test the Effect of Yellow Fever Vaccination in a Background of Japanese Encephalitis Antibodies. Completed NCT01943305 Phase 2
22 Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVaxâ„¢-JE) and Yellow Fever Vaccine (STAMARIL®) Completed NCT00982137 Phase 2
23 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
24 Safety of ChimeriVaxâ„¢ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
25 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
26 Immunogenicity and Safety of ChimeriVaxâ„¢ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
27 Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants Completed NCT00436007 Phase 2
28 Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection Recruiting NCT04267809 Phase 2 Metformin Hydrochloride;Calcium and Vitamin D
29 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination Recruiting NCT04269265 Phase 1, Phase 2
30 Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults Active, not recruiting NCT04942210 Phase 2
31 Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril in Adults Active, not recruiting NCT05011123 Phase 2
32 An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Not yet recruiting NCT05568953 Phase 2
33 A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults Completed NCT02743455 Phase 1 ISA-720
34 Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults Completed NCT04142086 Phase 1
35 Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) Completed NCT03776786 Phase 1
36 Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults. Completed NCT00995865 Phase 1
37 Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D) Completed NCT00254826 Phase 1
38 A Double Blind, Randomized, Placebo-Controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated Yellow Fever Virus Vaccine, HydroVax-002 YFV, in Healthy Adults Active, not recruiting NCT05172544 Phase 1
39 A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19 Terminated NCT03891420 Phase 1 Galidesivir;Placebo
40 Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC Unknown status NCT04235361
41 Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children Unknown status NCT02990182
42 Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study Unknown status NCT04416477
43 Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study Unknown status NCT02383680
44 Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers Unknown status NCT03938597
45 Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military, Participants of "Dose-response Study of Yellow Fever Vaccine 17DD Produced by Bio-Manguinhos / Fiocruz" in 2009 Completed NCT03338231
46 A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Subcutaneous Immunisation With Either "Varilrix" Varicella-zoster Vaccine, "Stamaril" Yellow Fever Vaccine or Saline Placebo in Healthy Adults With Evidence of Pre-existing Immunity to Varicella-zoster and no Existing Immunity to Yellow Fever. Completed NCT01765413
47 Duration of Immunity After Two Doses of Vaccine Against Yellow Fever in Adults Completed NCT02572518
48 Randomized Evaluation of a Conditional Cash Transfer Program for Routine Immunizations of Infants in Nigeria Completed NCT03870061
49 Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea Completed NCT03541694
50 Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults Completed NCT00616356

Search NIH Clinical Center for Yellow Fever

Cochrane evidence based reviews: yellow fever

Sources

Genetic Tests for Yellow Fever

About this section
Sources

Anatomical Context for Yellow Fever

About this section

Organs/tissues related to Yellow Fever:

MalaCards : Liver, Kidney, Skin, Lymph Node, T Cells, Salivary Gland, Bone Marrow
Sources

Publications for Yellow Fever

About this section

Articles related to Yellow Fever:

(show top 50) (show all 6897)
# Title Authors PMID Year
1
The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-A resolution. 53 62
12855689 2003
2
Isolation and expression of a sterol carrier protein-2 gene from the yellow fever mosquito, Aedes aegypti. 53 62
12542635 2003
3
Biochar: An environmentally friendly platform for construction of a SARS-CoV-2 electrochemical immunosensor. 62
36334678 2023
4
Development of an optical sandwich ELONA using a pair of DNA aptamers for yellow fever virus NS1. 62
36208558 2023
5
Peptide Microarrays for Flavivirus Diagnosis. 62
36152289 2023
6
Antiviral alkaloid principles of the plant family Amaryllidaceae. 62
36240608 2023
7
Quantitative real time PCR detection of Saboya virus: A flavivirus member of yellow fever genetic group. 62
36328081 2023
8
Establishment of Vero cell lines persistently harboring a yellow fever virus 17D subgenomic replicon. 62
36152929 2022
9
Effects of blood meal sources on the biological characteristics of Aedes aegypti and Culex pipiens (Diptera: Culicidae). 62
36187452 2022
10
Predicting the Effects of Climate Change on Dengue Vector Densities in Southeast Asia through Process-Based Modeling. 62
36473499 2022
11
Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines. 62
33974507 2022
12
Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo. 62
35249454 2022
13
RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region. 62
36464077 2022
14
Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice. 62
36471432 2022
15
Dataset of vector mosquito images. 62
36164301 2022
16
Assessing single-locus CRISPR/Cas9-based gene drive variants in the mosquito Aedes aegypti via single-generation crosses and modeling. 62
36250791 2022
17
Factors enhancing the transmission of mosquito-borne arboviruses in Africa. 62
36278029 2022
18
Multidisciplinary approach for surveillance and risk identification of yellow fever and other arboviruses in Colombia. 62
36277089 2022
19
Seasonal variation in the chemical composition and larvicidal activity against Aedes aegypti L. of essential oils from Brazilian Amazon. 62
36270431 2022
20
Urbanization of Aedes mosquito populations and evolution of arboviral disease risk in Africa. 62
36332839 2022
21
A mass rearing cost calculator for the control of Culex quinquefasciatus in Hawai'i using the incompatible insect technique. 62
36471389 2022
22
The interaction between the Dbf4 ortholog Chiffon and Gcn5 is conserved in Dipteran insect species. 62
35789507 2022
23
Anopheles (Kerteszia) cruzii infected by Plasmodium in the Atlantic Forest indicates that the malaria transmission cycle is maintained even after howler monkeys' population decline. 62
36208309 2022
24
A highly expressed odorant receptor from the yellow fever mosquito, AaegOR11, responds to (+)- and (-)-fenchone and a phenolic repellent. 62
36347453 2022
25
Walter Reed & Yellow Fever. 62
35057602 2022
26
Risk assessment of urban yellow fever virus transmission in Kenya: is Aedes aegypti an efficient vector? 62
35387573 2022
27
Occurrence of the Sylvatic Yellow Fever Vector Mosquito Haemagogus leucocelaenus (Diptera: Culicidae) in an Atlantic Forest Fragment of the Touristic State of Rio de Janeiro, Brazil. 62
36239293 2022
28
Estimation of yellow fever incidence in Togo between 2010 and 2020. 62
36208863 2022
29
A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus. 62
36199277 2022
30
Yellow fever resurgence: An avoidable crisis? 62
36323723 2022
31
New recommendation on yellow fever booster vaccination in Germany. 62
36342037 2022
32
A chromosome-level assembly of the widely used Rockefeller strain of Aedes aegypti, the yellow fever mosquito. 62
36086997 2022
33
Another neglected tropical disease yellow fever re-emerges in African countries: Potential threat in the COVID-19 era which needs comprehensive investigations - Correspondence. 62
36368420 2022
34
Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination. 62
36404054 2022
35
CRISPR-Cas9 Genome Editing Uncovers the Mode of Action of Methoprene in the Yellow Fever Mosquito, Aedes aegypti. 62
36374965 2022
36
Guiding yellow fever vaccination strategy worldwide: booster = better? 62
36380420 2022
37
Viral kinetics in sylvatic yellow fever cases. 62
36316804 2022
38
Parasites and Other Infectious Agents in Non-human Primates of Argentina. 62
36406044 2022
39
Novel approach based on GQD-PHB as anchoring platform for the development of SARS-CoV-2 electrochemical immunosensor. 62
36257733 2022
40
High prevalence of canine heartworm, Dirofilaria immitis, in pet dogs in south Texas, USA, with evidence of Aedes aegypti mosquitoes contributing to transmission. 62
36329477 2022
41
Publishing data to support the fight against human vector-borne diseases. 62
36329618 2022
42
Past, present and future distribution of the yellow fever mosquito Aedes aegypti: The European paradox. 62
35907522 2022
43
Marker-assisted mapping enables forward genetic analysis in Aedes aegypti, an arboviral vector with vast recombination deserts. 62
36083009 2022
44
Autoantibodies against type I IFNs in patients with critical influenza pneumonia. 62
36112363 2022
45
Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity. 62
36116380 2022
46
Neuroanatomical basis of sexual dimorphism in the mosquito brain. 62
36277452 2022
47
What sounds like Aedes, acts like Aedes, but is not Aedes? Lessons from dengue virus control for the management of invasive Anopheles. 62
36427517 2022
48
Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection. 62
36445148 2022
49
Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses. 62
35714271 2022
50
Does severe hypoxia during irradiation of Aedes aegypti pupae improve sterile male performance? 62
36443811 2022
Sources

Variations for Yellow Fever

About this section
Sources

Expression for Yellow Fever

About this section
Search GEO for disease gene expression data for Yellow Fever.
Sources

Pathways for Yellow Fever

About this section

Pathways related to Yellow Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.92 CCL2 CCL5 CCR5 CXCL10 IFNAR1 IFNB1
2
ERK Signaling 64
Show member pathways
 13.88 CCL2 CCL5 CCR5 CXCL10 IL17A IL1A
3
Disease 66
Show member pathways
 13.85 STAT1 RIGI IRF7 IL6 IL1B IL1A
4
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.69 CCL2 CCL5 CCR5 CXCL10 IFNB1 IL17A
5
TGF-Beta Pathway 64
Show member pathways
 13.62 STAT1 IL6 IL5 IL4 IL1B IL1A
6
Akt Signaling 64
Show member pathways
 13.49 STAT1 IL6 IL5 IL4 IL1B IL1A
7
PAK Pathway 64
Show member pathways
 13.39 IL6 IL5 IL4 IL1B IL1A IL17A
8
Cytokine Signaling in Immune system 66
Show member pathways
 13.17 CCL2 CCL5 CCR5 CXCL10 IFNAR1 IFNB1
9
CCR5 Pathway in Macrophages 64
Show member pathways
 12.88 STAT1 CXCL10 CCR5 CCL5 CCL2
10
Toll-like receptor signaling pathway 74
Show member pathways
 12.83 CCL5 CXCL10 EIF2AK4 IFNAR1 IFNB1 IL1A
11
Malignant pleural mesothelioma 74
12.77 CCL2 CCL5 CXCL10 IL1B IL6 STAT1
12
IL-1 Family Signaling Pathways 65
Show member pathways
 12.67 STAT1 IRF7 IL6 IL1B IL1A
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.64 STAT1 IL6 IL1B IL17A CCL2
14
Interferon gamma signaling 66
Show member pathways
 12.64 IFNAR1 IFNB1 IRF7 OAS1 RIGI RSAD2
15
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.54 IRF7 IL6 IL1B IFNB1
16
Bacterial infections in CF airways 22
Show member pathways
 12.53 CXCL10 IFNB1 IL1A IL1B IL4 IL6
17
Cytosolic sensors of pathogen-associated DNA 66
Show member pathways
 12.52 CCL5 CXCL10 IFNB1 IL1B IL6 IRF7
18
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66
Show member pathways
 12.48 RIGI IRF7 IFNB1 CXCL10
19
Toll Comparative Pathway 64
Show member pathways
 12.34 STAT1 IL6 IL1B IL1A
20
IL-17 Family Signaling Pathways 65
Show member pathways
 12.32 CCL2 CXCL10 IL17A IL6
21
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.27 CCR5 IFNAR1 IFNB1 IL17A IL1A IL1B
22
T-cell activation SARS-CoV-2 74
Show member pathways
 12.25 IL5 IL4 IL17A IFNB1 IFNAR1
23
Neuroinflammation and glutamatergic signaling 74
12.2 STAT1 IL6 IL4 IL1B IL1A
24
Ebola virus infection in host 74
12.12 STAT1 RIGI IRF7 IL4
25
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 12.11 CXCL10 CCR5 CCL5 CCL2
26
Spinal cord injury 74
12.1 IL6 IL4 IL1B IL1A CXCL10 CCL2
27
MAPK Pathway 70
Show member pathways
 12.09 STAT1 IL5 IL1B IL1A
28
Senescence and autophagy in cancer 74
12.06 IRF7 IL6 IL1B IL1A IFNB1
29
IL12-mediated signaling events 61
Show member pathways
 12.04 STAT1 IL4 IL1B CCR5
30
Interleukin-4 and Interleukin-13 signaling 66
12.03 STAT1 IL6 IL4 IL1B IL1A IL17A
31
IL27-mediated signaling events 61
Show member pathways
 12 STAT1 IL6 IL1B IL17A
32
Th17 Differentiation 65
Show member pathways
 11.99 IL17A IL1B IL4 IL6 STAT1
33
Host-pathogen interaction of human coronaviruses - interferon induction 74
Show member pathways
 11.98 STAT1 RIGI OAS1 IRF7 IFNB1 IFNAR1
34
Allograft rejection 74
11.96 STAT1 IL5 IL4 IL1B IL1A IL17A
35
Interferon Pathway 64
11.95 STAT1 IL6 IFNB1 IFNAR1
36
CCL18 signaling pathway 74
11.91 IL6 CCR5 CCL2
37
Innate Lymphoid Cells Differentiation 65
11.89 IL5 IL4 IL1B IL17A
38
NF-kappaB Signaling 3
11.88 CCL2 CCL5 CXCL10 IL17A IL1B IL4
39
Glucocorticoid receptor regulatory network 61
11.87 STAT1 IL6 IL5 IL4
40
Burn wound healing 74
11.85 IL6 IL1B IFNB1 CCL2
41
Th17 cell differentiation pathway 74
11.85 STAT1 IL6 IL4 IL1B IL17A
42
AP-1 transcription factor network 61
11.81 IL6 IL5 IL4 CCL2
43
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.8 IL6 IFNB1 CCL2
44
Acute viral myocarditis 74
11.79 CCR5 IL6 STAT1
45
Regulation of nuclear SMAD2/3 signaling 61
11.78 IRF7 IL5 IFNB1
46
Dendritic Cells Developmental Lineage Pathway 65
11.78 IL6 IL1B IFNB1
47
Inflammatory bowel disease signaling 74
Show member pathways
 11.77 STAT1 IL6 IL5 IL4 IL1A
48
Interleukin-6 family signaling 66
Show member pathways
 11.76 STAT1 IL6 CCL2
49
IL3-mediated signaling events 61
Show member pathways
 11.76 STAT1 IL5 CCL2
50
Lung fibrosis 74
11.75 IL6 IL5 IL4 IL1B CCL5 CCL2
Sources

GO Terms for Yellow Fever

About this section

Cellular components related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.96 IL6 IL5 IL4 IL1B IL1A IL17A
2 extracellular region GO:0005576 9.66 CCL2 CCL5 CXCL10 IFNB1 IL17A IL1A

Biological processes related to Yellow Fever according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.57 CXCL10 IFNB1 IL17A IL1A IL1B IL4
2 cell-cell signaling GO:0007267 10.33 IL1B IL17A CXCL10 CCR5 CCL5
3 inflammatory response GO:0006954 10.32 CCL2 CCL5 CCR5 CXCL10 IL17A IL1A
4 chemotaxis GO:0006935 10.28 CXCL10 CCR5 CCL5 CCL2
5 MAPK cascade GO:0000165 10.27 IL1B CCR5 CCL5 CCL2
6 positive regulation of DNA-binding transcription factor activity GO:0051091 10.25 IL1B IL5 IL6 RIGI
7 immune system process GO:0002376 10.21 EIF2AK4 IL17A IRF7 OAS1 RIGI RSAD2
8 neutrophil chemotaxis GO:0030593 10.2 CCL2 CCL5 CXCL10 IL1B
9 chemokine-mediated signaling pathway GO:0070098 10.19 CXCL10 CCR5 CCL5 CCL2
10 positive regulation of tumor necrosis factor production GO:0032760 10.19 RIGI OAS1 IL6 IL1A IL17A
11 positive regulation of T cell proliferation GO:0042102 10.18 IL6 IL4 IL1B CCL5
12 cellular response to lipopolysaccharide GO:0071222 10.18 CCL2 CCR5 CXCL10 IL1A IL1B IL6
13 response to lipopolysaccharide GO:0032496 10.16 IL1B IL1A IFNAR1 CXCL10
14 regulation of insulin secretion GO:0050796 10.16 IL6 IL1B CCL5
15 cellular response to organic cyclic compound GO:0071407 10.16 CCL2 CCL5 IL1B STAT1
16 positive regulation of interleukin-6 production GO:0032755 10.16 RIGI IL6 IL1B IL1A IL17A
17 immune response GO:0006955 10.16 CCL2 CCL5 CCR5 CXCL10 IL17A IL1A
18 monocyte chemotaxis GO:0002548 10.15 CCL2 CCL5 IL6
19 negative regulation of viral genome replication GO:0045071 10.15 RSAD2 OAS1 IFNB1 CCL5
20 positive regulation of interferon-beta production GO:0032728 10.14 RIGI OAS1 IRF7
21 receptor signaling pathway via JAK-STAT GO:0007259 10.14 STAT1 IFNB1 IFNAR1 CCL2
22 lipopolysaccharide-mediated signaling pathway GO:0031663 10.13 IL1B CCL5 CCL2
23 type I interferon-mediated signaling pathway GO:0060337 10.13 IFNAR1 IFNB1 IRF7 STAT1
24 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.11 IL6 IL5 CCL5
25 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.11 IL1A IL1B IL4
26 positive regulation of vascular endothelial growth factor production GO:0010575 10.1 IL6 IL1B IL1A
27 cellular response to virus GO:0098586 10.1 OAS1 IL6 IFNB1 IFNAR1 CXCL10 CCL5
28 cellular response to interferon-beta GO:0035458 10.09 STAT1 OAS1 IFNB1
29 positive regulation of interferon-alpha production GO:0032727 10.08 STAT1 RIGI IRF7
30 antiviral innate immune response GO:0140374 10.07 CXCL10 OAS1 RIGI
31 cytokine-mediated signaling pathway GO:0019221 10.06 CCL2 IFNAR1 IFNB1 IL1A IL1B IL5
32 defense response GO:0006952 10.04 STAT1 IFNB1 CXCL10 CCR5
33 positive regulation of defense response to virus by host GO:0002230 10.03 STAT1 RIGI IL4 EIF2AK4
34 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.99 RSAD2 IL6 IL4
35 negative regulation of macrophage apoptotic process GO:2000110 9.97 IRF7 CCR5
36 positive regulation of immature T cell proliferation in thymus GO:0033092 9.97 IL1B IL1A
37 cellular response to interleukin-17 GO:0097398 9.95 IL1B CXCL10
38 fever generation GO:0001660 9.92 IL1A IL1B
39 defense response to virus GO:0051607 9.89 STAT1 RSAD2 RIGI OAS1 IRF7 IL6
40 positive regulation of cellular respiration GO:1901857 9.88 IFNAR1 IL4 OAS1
41 response to virus GO:0009615 9.5 RSAD2 RIGI OAS1 IRF7 IFNB1 IFNAR1

Molecular functions related to Yellow Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 IL6 IL5 IL4 IL1B IL1A IL17A
Sources

Sources for Yellow Fever

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....